Oral FMT Raised Peanut Tolerance in 6 of 15 Allergic Adults, Early Study Finds
Updated
Updated · Healthline · Aug 15
Oral FMT Raised Peanut Tolerance in 6 of 15 Allergic Adults, Early Study Finds
3 articles · Updated · Healthline · Aug 15
Summary
Six of 15 adults with peanut allergy tolerated more peanut protein after a single oral fecal microbiome transplant in a small Phase 1 trial, with no serious adverse events reported.
Ten participants took 36 frozen donor-derived capsules over one or two days and three improved after four months; another three of five improved after receiving antibiotics before FMT.
Mouse experiments mirrored the human signal: transplants from responders protected mice and boosted RORγt+ regulatory T cells, pointing to an immune mechanism tied to gut microbes.
Bacteroides-linked bile acid metabolism appeared central, as removing the bile salt hydrolase enzyme in mice erased the added peanut tolerance.
Researchers say FMT is not ready for clinical use and want larger trials of a more purified microbiota therapy, with possible applications still 10 to 15 years away if results hold.